Bidirectional Mendelian Randomization Analysis of Genetic Proxies of Plasma Fatty Acids and Pre-Eclampsia Risk

Overview

Journal Nutrients

Date 2024 Nov 9

PMID 39519582

Authors

Jingqi Zhou

Shuo Jiang

Dangyun Liu

Xinyi Li

Ziyi Zhou

Zhiheng Wang

Hui Wang

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have reported associations between fatty acids and the risk of pre-eclampsia. However, the causality of these associations remains uncertain. This study postulates a causal relationship between specific plasma fatty acids and pre-eclampsia or other maternal hypertensive disorders (PE-HTPs). To test this hypothesis, two-sample bidirectional Mendelian randomization (MR) analyses were employed to determine the causality effects.

Methods: Single-nucleotide polymorphisms associated with PE-HTPs and fatty acids were obtained from a genome-wide association study (GWAS) of European ancestry. Bidirectional MR analyses were conducted using methods such as inverse variance weighted, MR-Egger, weighted median, simple mode, and weighted mode. Sensitivity analyses, including tests for heterogeneity, horizontal pleiotropy, and co-localization, were conducted to assess the robustness of MR results.

Results: The analyses revealed causal relationships between PE-HTPs and several fatty acids, including monounsaturated fatty acid (MUFA), omega-6 fatty acid (-6 FA), linoleic acid (LA), docosahexaenoic acid (DHA), and the PUFA/MUFA ratio. Genetically predicted higher risk of PE-HTPs was significantly associated with lower plasma -6 FA (OR = 0.96, 95% CI: 0.93-0.99), particularly LA (OR = 0.95, 95% CI: 0.92-0.98). Conversely, increased DHA (OR = 0.86, 95% CI: 0.78-0.96) and a higher PUFA/MUFA ratio (OR = 0.86, 95% CI: 0.76-0.98) were associated with a reduced risk of PE-HTPs. Elevated MUFA levels (OR = 1.12, 95% CI: 1.00-1.25) were related to an increased risk.

Conclusions: This study provides robust genetic evidence supporting bidirectional causal relationships between PE-HTPs and specific plasma fatty acids, underscoring the critical role of fatty acid metabolism in maternal hypertensive disorders.

References

Irwinda R, Hiksas R, Siregar A, Saroyo Y, Wibowo N . Long-chain polyunsaturated fatty acid (LC-PUFA) status in severe preeclampsia and preterm birth: a cross sectional study. Sci Rep. 2021; 11(1):14701. PMC: 8289913. DOI: 10.1038/s41598-021-93846-w. View

Alvino G, Cozzi V, Radaelli T, Ortega H, Herrera E, Cetin I . Maternal and fetal fatty acid profile in normal and intrauterine growth restriction pregnancies with and without preeclampsia. Pediatr Res. 2008; 64(6):615-20. DOI: 10.1203/PDR.0b013e31818702a2. View

Julkunen H, Cichonska A, Slagboom P, Wurtz P . Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. Elife. 2021; 10. PMC: 8172246. DOI: 10.7554/eLife.63033. View

Elhakeem A, Ronkainen J, Mansell T, Lange K, Mikkola T, Mishra B . Effect of common pregnancy and perinatal complications on offspring metabolic traits across the life course: a multi-cohort study. BMC Med. 2023; 21(1):23. PMC: 9850719. DOI: 10.1186/s12916-022-02711-8. View

Muzsik A, Jelen H, Chmurzynska A . Metabolic syndrome in postmenopausal women is associated with lower erythrocyte PUFA/MUFA and n-3/n-6 ratio: A case-control study. Prostaglandins Leukot Essent Fatty Acids. 2020; 159:102155. DOI: 10.1016/j.plefa.2020.102155. View

Gray N, Stoodley I, Wood L, Collins C, Brown L, Rae K . Omega-3 Fatty Acids during Pregnancy in Indigenous Australian Women of the Gomeroi Gaaynggal Cohort. Nutrients. 2023; 15(8). PMC: 10145055. DOI: 10.3390/nu15081943. View

Richardson T, Leyden G, Wang Q, Bell J, Elsworth B, Davey Smith G . Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. PLoS Biol. 2022; 20(2):e3001547. PMC: 8906647. DOI: 10.1371/journal.pbio.3001547. View

Dangat K, Mehendale S, Yadav H, Kilari A, Kulkarni A, Taralekar V . Long-chain polyunsaturated fatty acid composition of breast milk in pre-eclamptic mothers. Neonatology. 2009; 97(3):190-4. DOI: 10.1159/000252971. View

Coscia A, Riboldi L, Spada E, Bertino E, Sottemano S, Barbagallo I . Preeclampsia and Its Impact on Human Milk Activin A Concentration. Nutrients. 2023; 15(19). PMC: 10574093. DOI: 10.3390/nu15194296. View

10.

Lin S, Brown D, Machiela M . LDtrait: An Online Tool for Identifying Published Phenotype Associations in Linkage Disequilibrium. Cancer Res. 2020; 80(16):3443-3446. PMC: 7442674. DOI: 10.1158/0008-5472.CAN-20-0985. View

11.

Kulkarni A, Mehendale S, Yadav H, Kilari A, Taralekar V, Joshi S . Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens Res. 2010; 33(6):561-7. DOI: 10.1038/hr.2010.31. View

12.

Wadhwani N, Patil V, Joshi S . Maternal long chain polyunsaturated fatty acid status and pregnancy complications. Prostaglandins Leukot Essent Fatty Acids. 2017; 136:143-152. DOI: 10.1016/j.plefa.2017.08.002. View

13.

Burchakov D, Kuznetsova I, Uspenskaya Y . Omega-3 Long-Chain Polyunsaturated Fatty Acids and Preeclampsia: Trials Say "No," but Is It the Final Word?. Nutrients. 2017; 9(12). PMC: 5748814. DOI: 10.3390/nu9121364. View

14.

Poornima I, Indaram M, Ross J, Agarwala A, Wild R . Hyperlipidemia and risk for preclampsia. J Clin Lipidol. 2022; 16(3):253-260. PMC: 10320742. DOI: 10.1016/j.jacl.2022.02.005. View

15.

Prieto-Sanchez M, Ruiz-Palacios M, Blanco-Carnero J, Pagan A, Hellmuth C, Uhl O . Placental MFSD2a transporter is related to decreased DHA in cord blood of women with treated gestational diabetes. Clin Nutr. 2016; 36(2):513-521. DOI: 10.1016/j.clnu.2016.01.014. View

16.

Jiang Y, Chen Y, Wei L, Zhang H, Zhang J, Zhou X . DHA supplementation and pregnancy complications. J Transl Med. 2023; 21(1):394. PMC: 10276458. DOI: 10.1186/s12967-023-04239-8. View

17.

Yang Y, Wang Y, Lv Y, Ding H . Dissecting the Roles of Lipids in Preeclampsia. Metabolites. 2022; 12(7). PMC: 9323219. DOI: 10.3390/metabo12070590. View

18.

Makrides M, Duley L, Olsen S . Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev. 2006; (3):CD003402. DOI: 10.1002/14651858.CD003402.pub2. View

19.

Fox R, Kitt J, Leeson P, Aye C, Lewandowski A . Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring. J Clin Med. 2019; 8(10). PMC: 6832549. DOI: 10.3390/jcm8101625. View

20.

Wang Y, Walsh S, Kay H . Placental tissue levels of nonesterified polyunsaturated fatty acids in normal and preeclamptic pregnancies. Hypertens Pregnancy. 2005; 24(3):235-45. DOI: 10.1080/10641950500281118. View